Karolina Pierzynowska

Dr. Karolina Pierzynowska

University of Gdańsk, Faculty of Biology
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Autophagy
Verified
Journal Article
Closed access
DKDaniel J. Klionsky
Daniel J. Klionsky
AAAmal Kamal Abdel-Aziz
Amal Kamal Abdel-Aziz
SASara Abdelfatah
Sara Abdelfatah
MAMahmoud Abdellatif
Mahmoud Abdellatif
AAAsghar Abdoli
Asghar Abdoli
CTChun-Kit Tong
Chun-Kit Tong

1 January 2018
Verified
Book Chapter
Closed access
CGCarlotta Giorgi
Carlotta Giorgi
SMSaverio Marchi
Saverio Marchi
ISInes Simoes
Ines Simoes
ZRZiyu Ren
Ziyu Ren
Giampaolo MorcianoGiampaolo Morciano
Giampaolo Morciano
MWMariusz Wieckowski
Mariusz Wieckowski

21 October 2021 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
WJWeronika Jaroszewicz
Weronika Jaroszewicz
JMJoanna Morcinek-Orłowska
Joanna Morcinek-Orłowska
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
LGLidia Gaffke
Lidia Gaffke
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Phage display technology, which is based on the presentation of peptide sequences on the surface of bacteriophage virions, was developed over 30 years ago. Improvements in phage display systems have allowed us to employ this method in numerous fields of biotechnology, as diverse as immunological and biomedical applications, the formation of novel materials and many others. The importance of phage display platforms was recognized by awarding the Nobel Prize in 2018 ‘for the phage display of peptides and antibodies’. In contrast to many review articles concerning specific applications of phage display systems published in recent years, we present an overview of this technology, including a comparison of various display systems, their advantages and disadvantages, and examples of applications in various fields of science, medicine and the broad sense of biotechnology. Other peptide display technologies, which employ bacterial, yeast and mammalian cells, as well as eukaryotic viruses and cell-free systems, are also discussed. These powerful methods are still being developed and improved; thus, novel sophisticated tools based on phage display and other peptide display systems are constantly emerging, and new opportunities to solve various scientific, medical and technological problems can be expected to become available in the near future.

Verified
Journal Article
Open access
PDF file
Łukasz GrabowskiŁukasz Grabowski
Łukasz Grabowski
Lidia GaffkeLidia Gaffke
Lidia Gaffke
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
ZCZuzanna Cyske
Zuzanna Cyske
MCMarta Choszcz
Marta Choszcz
Alicja WęgrzynAlicja Węgrzyn
Alicja Węgrzyn
Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3–9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.

1 April 2019 in Neuropharmacology
Verified
Journal Article
Closed access
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
MPMagdalena Podlacha
Magdalena Podlacha
Lidia GaffkeLidia Gaffke
Lidia Gaffke
IMIrena Majkutewicz
Irena Majkutewicz
JMJagoda Mantej
Jagoda Mantej
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn

14 March 2018 in Metabolic Brain Disease
Verified
Journal Article
Open access
PDF file
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
Lidia GaffkeLidia Gaffke
Lidia Gaffke
ZCZuzanna Cyske
Zuzanna Cyske
MPMichał Puchalski
Michał Puchalski
EREstera Rintz
Estera Rintz
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Autophagy is a process of degradation of macromolecules in the cytoplasm, particularly proteins of a long half-life, as well as whole organelles, in eukaryotic cells. Lysosomes play crucial roles during this degradation. Autophagy is a phylogenetically old, and evolutionarily conserved phenomenon which occurs in all eukaryotic cells. It can be found in yeast Saccharomyces cerevisiae, insect Drosophila melanogaster, and mammals, including humans. Its high importance for cell physiology has been recognized, and in fact, dysfunctions causing impaired autophagy are associated with many severe disorders, including cancer and metabolic brain diseases. The types and molecular mechanisms of autophagy have been reviewed recently by others, and in this paper they will be summarized only briefly. Regulatory networks controlling the autophagy process are usually described as negative regulations. In contrast, here, we focus on different ways by which autophagy can be stimulated. In fact, activation of this process by different factors or processes can be considered as a therapeutic strategy in metabolic neurodegenerative diseases. These aspects are reviewed and discussed in this article.